---
title: "management of muscle invasive disease"
slug: "management-of-muscle-invasive-disease"
date: "2023-11-22"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[bladder cancer]]

# management of muscle invasive disease

- Radical cystectomy is tx of choice for muscle invasive dz w/ urinary diversion
- Neoadjuvant cisplatin-based chemo prior to cystectomy improves OS (NEJM 2003;349:859; Lancet 2003;361:1927).
  - Regimens include
    - dose-dense (dd)MVAC methotrexate,
    - vinblastine,
    - doxorubicin,
    - cisplatin (JCO 2014;32:1895; JCO 2014;32:1889) or GC-gemcitabine,
    - cisplatin (Clin Genitourin Cancer 2020;18:387)
- Bladder preservation options include trimodality tx:
  - TURBT, followed by concurrent chemoradiation (NEJM 2012;366:1477).
  - Pt selection key,
    - w/ up to 40% requiring cystectomy for tx failure or dz recurrence.
    - Criteria:
      - Eligibility for complete TURBT,
      - adequate bladder fxn,
      - UC histology,
      - early stage (T2),
      - no multifocal dz & no hydronephrosis
- No completed prospective RCT establishes adjuvant chemo after radical cystectomy,
  - though meta-analyses show survival benefit (Eur Urol 2014;66:42)
- Emerging data in high-risk pts shows â†‘ disease free survival (DFS) w/ adjuvant nivolumab (N Engl J Med 2021;384:2102)
